Abstract.
Progesterone and the antiprogestin RU38486 have been reported as non-transported modulators of P-glycoprotein-mediated drug efflux. However, their hormonal properties limit their potential for clinical trials. The present work shows that some derivatives from either progesterone/RU38486 or estradiol, displaying differential interaction with hormone receptors, bind to P-glycoprotein and chemosensitize the growth of MDR1-transfected cells to vinblastine more strongly than does RU38486. Structure comparison of the compounds indicates that the highly hydrophobic estradiol derivative RU49953, which does not interact with any hormone receptor, inhibits P-glycoprotein-mediated drug efflux very efficiently, as monitored by flow cytometry, and prevents drug site photoaffinity labeling by azidopine. It induces a much higher chemosensitization than the well-known P-glycoprotein modulator verapamil, which is itself more efficient than RU38486. RU49953 therefore constitutes a promising new lead for steroid-type modulators of multidrug resistance.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received 24 December 2002; accepted 17 January 2003
RID="h1"
RID="h1"
RID="*"
ID="h1"F. J. Perez-Victoria and G. Conseil contributed equally to his work.
ID="*"Corresponding author.
Rights and permissions
About this article
Cite this article
Perez-Victoria, F., Conseil, G., Munoz-Martinez, F. et al. RU49953: a non-hormonal steroid derivative that potently inhibits P-glycoprotein and reverts cellular multidrug resistance. CMLS, Cell. Mol. Life Sci. 60, 526–535 (2003). https://doi.org/10.1007/s000180300044
Issue Date:
DOI: https://doi.org/10.1007/s000180300044